Dr. Reddy's Laboratories announces the launch of Cinacalcet Tablets in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

The Sensipar brand and generic market had U.S. sales of approximately $312 million MAT for the most recent twelve months ending in July 2020 according to IQVIA Health*.

Dr. Reddy's Cinacalcet Tablets are available in 30 mg, 60 mg, and 90 mg tablets in a bottle count size of 30.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.5187.05 as compared to the previous close of Rs. 5083.5. The total number of shares traded during the day was 179198 in over 13644 trades.

The stock hit an intraday high of Rs. 5315.45 and intraday low of 5090. The net turnover during the day was Rs. 932621594.

Sensipar is a trademark of Amgen Inc.

*IQVIA Retail and Non-Retail MAT July 2020

Source : Equity Bulls

Keywords